Norge - norsk - Statens legemiddelverk

stada arzneimittel ag - cinacalcethydroklorid - tablett, filmdrasjert - 30 mg

Norge - norsk - Statens legemiddelverk

stada arzneimittel ag - cinacalcethydroklorid - tablett, filmdrasjert - 60 mg

Norge - norsk - Statens legemiddelverk

stada arzneimittel ag - cinacalcethydroklorid - tablett, filmdrasjert - 90 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

stada arzneimittel ag - teriparatide - osteoporose - kalsiumhomeostase - movymia er indisert hos voksne. behandling av osteoporose hos postmenopausale kvinner og hos menn med økt risiko for brudd. hos postmenopausale kvinner er det vist en signifikant reduksjon i forekomsten av vertebrale og ikke vertebrale frakturer, men ikke hoftefrakturer. behandling av osteoporose assosiert med vedvarende systemisk glukokortikoid terapi hos kvinner og menn med økt risiko for brudd.

Norge - norsk - Statens legemiddelverk

vale pharmaceuticals limited - paracetamol / ibuprofen - tablett, filmdrasjert - 500 mg / 150 mg

Norge - norsk - Statens legemiddelverk

karo pharma as - ibuprofen - mikstur, suspensjon med jordbærsmak - 20 mg/ ml

Den europeiske union - norsk - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiske midler - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. for ytterligere informasjon om human epidermal growth factor receptor 2 (her2) status, se avsnitt 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. for ytterligere informasjon om her2-status, se avsnitt 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Norge - norsk - Statens legemiddelverk

stada arzneimittel ag - bortezomibmannitolboronat - injeksjonsvæske, oppløsning - 2.5 mg/ ml

Norge - norsk - Statens legemiddelverk

karo pharma as - ibuprofen - mikstur, suspensjon - 40 mg/ ml

Den europeiske union - norsk - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, intestinal betennelsesdempende / antiinfective agents - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.